Hims & Hers Health

HIMS

Market cap $9.05B

Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.

Traders like heavily shorted stocks for two main reasons: either to bet on a decline in the company's value, or to profit from a short squeeze.

The regulatory changes surrounding the weight loss treatment industry are having a large impact on Hims & Hers (HIMS 1.83%) stock.

Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product offerings and logistics, driving subscriber and revenue growth, despite near-term margin compression and increased capital expenditures. The upcoming Zava acquisition and potential regulatory changes could further boost HIMS's international presence and revenue, with DCF-based valuations suggesting significant upside.

HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.

Several big-name stocks just announced notable increases to their share buyback programs. These actions signal confidence, indicating that these companies' management teams may see value in their stocks.

Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization and new offerings like Labs via Quest Diagnostics. Short-term free cash flow growth will be slower due to increased capex, but management guides for $2.3B revenue in 2025 and $6.5B by 2030.

HIMS expands its connected care model with new diagnostics, hormonal health services and at-home testosterone treatments.

Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?

Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie NYSE: ABBV, Eli Lilly NYSE: LLY, Pfizer NYSE: PFE, and Merck NYSE: MRK—and their lineup of game-changing drugs—receive the lion's share of attention.